bioAffinity Technologies Investor Relations Material
Latest events
Status Update
bioAffinity Technologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from bioAffinity Technologies Inc
Access all reports
bioAffinity Technologies Inc. is a biotechnology company focused on addressing the critical need for non-invasive, early-stage cancer diagnosis and targeted cancer treatments. The company's flagship product, CyPath Lung, is a diagnostic test for the early detection of lung cancer. Additionally, the company is involved in research and development efforts aimed at creating targeted diagnostics and therapeutics to combat cancer, leveraging its core porphyrin platform technology. The company is headquartered in is headquartered in San Antonio, Texas, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
BIAF
Country
🇺🇸 United States